Skip to content

Jazz Pharmaceuticals

US · JAZZ #1123 by market cap Listed 1970
230.26 -6.19 -2.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Citi Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $325
    Market Newswire · 2026/10/27
  • Company notice
    Shanghai Sanyou Medical Co., Ltd: Voluntary Disclosure Notice on the JAZZ System, a spinal fixed connector system, obtained a medical device registration certificate
    SZSI · 2025/7/16
  • Rating change
    A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $275 to $319
    Market Newswire · 2026/11/4
  • Rating change
    Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $271
    Market Newswire · 2026/10/13
  • Rating change
    RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $296
    Market Newswire · 2026/10/8
  • Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $308
    Market Newswire · 2026/11/16
  • Company notice
    Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
    SEC · 2025/8/12
  • Company notice
    Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
    SEC · 2024/11/13
  • Company notice
    Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
    SEC · 2024/10/22
  • Company notice
    Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
    SEC · 2024/8/7
  • Rating change
    Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $314
    Market Newswire · 2026/10/21
  • Rating change
    J.P. Morgan Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $300
    Market Newswire · 2026/10/28
  • Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $330
    Market Newswire · 2026/11/12
  • Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $324
    Market Newswire · 2026/11/13
  • UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337
    Market Newswire · 2026/10/28
  • Rating change
    Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/10/16
  • Form 144 | Jazz Pharmaceuticals(JAZZ.US) Director Proposes to Sell 16.24 Million in Common Stocks
    Market Newswire · 2026/11/7
  • Rating change
    A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $275 to $325
    Market Newswire · 2026/11/3
  • Rating change
    Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $286
    Market Newswire · 2026/10/7
  • Rating change
    BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $313
    Market Newswire · 2026/10/9
  • Rating change
    Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/9/28
  • Rating change
    Citi Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $325
    Market Newswire · 2026/9/30
  • Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B Estimate
    Benzinga · 2026/11/3
  • Rating change
    UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337
    Market Newswire · 2026/9/14
  • Rating change
    Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
    Market Newswire · 2026/9/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.

Jazz Pharmaceuticals discussion 0 comments

Add a comment